Target

BTK

Tyrosine-protein kinase BTK

44open trials
78trials in total
84publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Trial
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
1 Mar 2027· PHASE4 · NOT_YET_RECRUITING· CTGOV
Trial
Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL
13 Jan 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
1 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor
11 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)
1 Nov 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Early Integration of CAR T-Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors.
1 Nov 2026· Hematological oncology· PUBMED
Publication
BTK Inhibitor Ibrutinib Reduces Bispecific Antibody-Related CRS Without Undermining the Anti-Tumor Efficacy.
28 Oct 2026· Cancer science· PUBMED
Publication
Clinical characteristics and outcome of a cohort of CLL patients with BTK T474 gatekeeper mutation.
16 Oct 2026· Blood advances· PUBMED
Publication
BTK inhibition suppresses neuroinflammation and neurodegeneration in amyotrophic lateral sclerosis.
5 Oct 2026· Brain : a journal of neurology· PUBMED
Publication
TLR9-dependent migration identifies different Chronic Lymphocytic Leukemia signaling states under BTK inhibition.
5 Oct 2026· Blood· PUBMED
Publication
Exploring Progressive Multiple Sclerosis and the Therapeutic Potential of BTK Inhibitors Based on EBV-driven B Cell-microglia Interactions.
1 Oct 2026· CNS & neurological disorders drug targets· PUBMED
Publication
Venetoclax consolidation deepens response and enables measurable residual disease-guided finite therapy in BTK inhibitor-treated chronic lymphocytic leukemia.
1 Oct 2026· Leukemia & lymphoma· PUBMED
Trial
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
29 Sept 2026· PHASE1 · RECRUITING· CTGOV
Publication
Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study.
24 Sept 2026· Cancer chemotherapy and pharmacology· PUBMED
Trial
Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.
15 Sept 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Timing matters: Impact of covalent BTK inhibitor dose modifications on outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia-A 7-year real-world study.
15 Sept 2026· Cancer· PUBMED
Publication
Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database.
4 Sept 2026· Frontiers in medicine· PUBMED
Publication
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
3 Sept 2026· Blood· PUBMED
Publication
Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis.
1 Sept 2026· Journal of cellular and molecular medicine· PUBMED
Publication
Polymeric nanoparticle platforms for ibrutinib delivery: tackling solubility, CYP3A4-mediated metabolism, and resistance to facilitate BTK-targeted therapy in solid tumours.
25 Aug 2026· Therapeutic delivery· PUBMED
Trial
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
24 Aug 2026· PHASE2 · RECRUITING· CTGOV
Publication
BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives.
20 Aug 2026· Cancers· PUBMED
Publication
BTK inhibitors are associated with a lower risk of myeloid neoplasms and non-melanoma skin cancer compared with chemoimmunotherapy in chronic lymphocytic leukemia: a propensity score-matched analysis.
10 Aug 2026· Leukemia· PUBMED
Publication
Cardiovascular Toxicity of BTK Inhibitors: A Patient-Centered Framework for Risk Stratification and Management.
8 Aug 2026· Journal of clinical medicine· PUBMED
Publication
The BTK inhibitor acalabrutinib inhibits the expression of PD-L1 on myeloid cells during inflammation.
4 Aug 2026· Molecular immunology· PUBMED
Trial
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
1 Aug 2026· PHASE2 · RECRUITING· CTGOV
Publication
Pretreatment With BTK Inhibitors Improved the Sensitivity of DLBCL Cells to CAR-T Cells in a Coculture System by Downregulating the Polarisation of M2 Macrophages.
1 Aug 2026· Journal of cellular and molecular medicine· PUBMED
Publication
HS1 loss drives cytoskeletal dysregulation and reduces sensitivity to BTK inhibition in chronic lymphocytic leukemia.
31 Jul 2026· Journal of leukocyte biology· PUBMED
Publication
Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study.
24 Jul 2026· Advances in therapy· PUBMED
Publication
Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors.
22 Jul 2026· Cancer discovery· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error